CN106511394A - 九香虫脂肪油提取物的新用途 - Google Patents
九香虫脂肪油提取物的新用途 Download PDFInfo
- Publication number
- CN106511394A CN106511394A CN201610979862.2A CN201610979862A CN106511394A CN 106511394 A CN106511394 A CN 106511394A CN 201610979862 A CN201610979862 A CN 201610979862A CN 106511394 A CN106511394 A CN 106511394A
- Authority
- CN
- China
- Prior art keywords
- aspongopus
- fat oil
- gastric ulcer
- oil extract
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000660877 Coridius Species 0.000 title claims abstract description 145
- 239000000284 extract Substances 0.000 title claims abstract description 99
- 239000010685 fatty oil Substances 0.000 title abstract 5
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 59
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 58
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 208000025865 Ulcer Diseases 0.000 claims abstract description 20
- 231100000397 ulcer Toxicity 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 208000002193 Pain Diseases 0.000 claims abstract description 10
- 230000036407 pain Effects 0.000 claims abstract description 10
- 241000700159 Rattus Species 0.000 claims description 52
- 210000002784 stomach Anatomy 0.000 claims description 42
- 239000007788 liquid Substances 0.000 claims description 35
- 238000000605 extraction Methods 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 210000001156 gastric mucosa Anatomy 0.000 claims description 13
- 210000001187 pylorus Anatomy 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 230000001175 peptic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 23
- 230000035876 healing Effects 0.000 abstract description 3
- 235000019197 fats Nutrition 0.000 description 98
- 239000003921 oil Substances 0.000 description 97
- 235000019198 oils Nutrition 0.000 description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 31
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000008107 starch Substances 0.000 description 13
- 235000019698 starch Nutrition 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 9
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 208000007882 Gastritis Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229960001380 cimetidine Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 235000019256 formaldehyde Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000023652 chronic gastritis Diseases 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- -1 flavone compound Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000628925 Coridius chinensis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000578422 Graphosoma lineatum Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000500891 Insecta Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别 | n | 溃疡指数( ±SD) | P值 |
空白组 | 8 | 0 | |
模型组 | 8 | 56.63±12.37 | |
阳性组 | 8 | 45.43±29.83 | 0.17 |
九香虫氨基酸高剂量组 | 8 | 44.50±22.91 | 0.11 |
九香虫氨基酸低剂量组 | 8 | 52.25±15.62 | 0.27 |
九香虫脂肪油高剂量组 | 8 | 25.50±17.08 | 0.0002** |
九香虫脂肪油低剂量组 | 8 | 8.50±6.63 | 0.0003** |
九香虫水煎液高剂量组 | 8 | 50.29±12.04 | 0.17 |
九香虫水煎液低剂量组 | 8 | 51.50±15.58 | 0.25 |
组别 | n | 溃疡指数(±SD) | P值 |
空白组 | 8 | 0 | - |
模型组 | 8 | 28.1211.22 | - |
阳性对照组 | 8 | 12.3310.76 | 0.011* |
九香虫氨基酸高剂量组 | 8 | 23.3811.20 | 0.205 |
九香虫氨基酸低剂量组 | 8 | 28.8813.81 | 0.453 |
九香虫脂肪油高剂量组 | 8 | 11.437.59 | 0.0029** |
九香虫脂肪油低剂量组 | 8 | 7.836.79 | 0.0010** |
水煎液高剂量组 | 8 | 32.8759.39 | 0.187 |
水煎液低剂量组 | 8 | 29.7512.56 | 0.394 |
组别 | n | 溃疡指数 | 溃疡抑制率(%) | P值 |
空白组 | 8 | 0 | 100 | - |
模型组 | 8 | 23.00±4.89 | - | - |
阳性对照组 | 8 | 13.00±4.19** | 43.47 | 0.004363469 |
九香虫氨基酸高剂量组 | 8 | 16.0±12.98 | 30.43 | 0.249607298 |
九香虫氨基酸低剂量组 | 8 | 13.5015.02 | 41.30 | 0.178577812 |
九香虫脂肪油高剂量组 | 8 | 10.33±5.49** | 54.22 | 0.001707684 |
九香虫脂肪油低剂量组 | 8 | 7.33±4.68** | 68.13 | 0.000207712 |
九香虫水煎液高剂量组 | 8 | 16.50±5.26 | 28.26 | 0.586037724 |
九香虫水煎液低剂量组 | 8 | 19.75±7.09 | 14.13 | 0.411983847 |
组别 | n | 溃疡指数 | 溃疡抑制率(%) |
空白组 | 12 | 0 | |
模型组 | 12 | 66.20±22.63 | - |
阳性对照组 | 12 | 25.00±17.51** | 62.24% |
九香虫脂肪油低剂量组 | 12 | 43.22±19.21* | 34.71% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610979862.2A CN106511394B (zh) | 2016-11-08 | 2016-11-08 | 九香虫脂肪油提取物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610979862.2A CN106511394B (zh) | 2016-11-08 | 2016-11-08 | 九香虫脂肪油提取物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106511394A true CN106511394A (zh) | 2017-03-22 |
CN106511394B CN106511394B (zh) | 2020-07-28 |
Family
ID=58349635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610979862.2A Active CN106511394B (zh) | 2016-11-08 | 2016-11-08 | 九香虫脂肪油提取物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106511394B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116870102A (zh) * | 2023-07-27 | 2023-10-13 | 北京力晟鸿吉信息科技发展有限公司 | 一种降血糖中药组合物及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1559447A (zh) * | 2004-02-18 | 2005-01-05 | 中国人民解放军军需大学 | 九香虫提取物及提取方法,及其医药用途和制剂 |
-
2016
- 2016-11-08 CN CN201610979862.2A patent/CN106511394B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1559447A (zh) * | 2004-02-18 | 2005-01-05 | 中国人民解放军军需大学 | 九香虫提取物及提取方法,及其医药用途和制剂 |
Non-Patent Citations (2)
Title |
---|
李会芳等: "正交设计优化九香虫脂肪油超临界CO2 萃取工艺", 《山西中医学院学报》 * |
王渭川等: "运用虫类药的经验", 《四川中医》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116870102A (zh) * | 2023-07-27 | 2023-10-13 | 北京力晟鸿吉信息科技发展有限公司 | 一种降血糖中药组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106511394B (zh) | 2020-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101199683A (zh) | 一种治疗皮肤病的中药及其制备方法 | |
CN105663000A (zh) | 一种白及保湿凝胶产品及其制备方法 | |
CN101450092B (zh) | 川木香提取物、含有该提取物的组合物及其用途 | |
CN103919854A (zh) | 密蒙花及其提取物在制备药物中的应用 | |
CN102526427A (zh) | 治疗胃肠疾病的中药组合物及质量检测方法 | |
CN102085257A (zh) | 一种桂枝茯苓微丸的制备方法 | |
CN101991811B (zh) | 一种治疗风湿关节疼痛、感冒头痛、脘腹疼痛、冻疮的中药组合物及其制备方法 | |
CN104055909A (zh) | 复方阿胶浆在制备经期保健的药物中的应用 | |
CN106511394A (zh) | 九香虫脂肪油提取物的新用途 | |
CN107266599B (zh) | 金针菇多糖、提取方法及其在制备治疗功能性便秘药物方面的应用 | |
CN101040891B (zh) | 昆明山海棠生物碱的制备方法 | |
AU2012325600B2 (en) | Pharmaceutical composition regulating blood fat and preparation process thereof | |
CN102784157B (zh) | 纤细薯蓣皂苷的用途以及含有纤细薯蓣皂苷的药物组合物 | |
CN102784230B (zh) | 一种治疗营养性贫血的药物组合物制剂 | |
CN102626407A (zh) | 异瑞香新素化合物在制备抗糖尿病药物中的应用 | |
CN106237181A (zh) | 一种治疗类风湿关节炎的中药组合物及其胶囊剂和制备方法 | |
CN100408055C (zh) | 一种治疗伤科疾病的中药组合物及其制备方法和质量控制方法 | |
CN108704036A (zh) | 一种治疗痛风的复方中药制剂及其制备方法 | |
CN103893512B (zh) | 一种治疗痛风性关节炎的中药组合物 | |
CN104069149A (zh) | 一种采用熊胆为基质的中药饮片炮制方法 | |
CN102579601A (zh) | 一种治疗类风湿性关节炎的药物组合物及其制备方法和用途 | |
CN102552481A (zh) | 一种通络降压中药组合物及其制备方法 | |
CN101991757A (zh) | 一种补肾助阳的中药组合物及其制备方法 | |
CN101618157B (zh) | 一种用于治疗秋燥感冒的药物组合物及其制备方法 | |
CN106858599A (zh) | 一种功能食品及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 030024 Shanxi city of Taiyuan province Jinci road section of No. 89 Patentee after: SHANXI University OF CHINESE MEDICINE Address before: No. 121 Daxue Street, Yuci District, Jinzhong City, Taiyuan City, Shanxi Province, 030619 Patentee before: SHANXI University OF TRADITIONAL CHINESE MEDICINE |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231107 Address after: No. 1701, No. 200 Jinyang Street, Taiyuan City, Shanxi Province 030006 Patentee after: Shanxi Zhongyuyuan Biotechnology Co.,Ltd. Address before: 030024 Shanxi city of Taiyuan province Jinci road section of No. 89 Patentee before: SHANXI University OF CHINESE MEDICINE |
|
TR01 | Transfer of patent right |